Genomic Cancer Panel & Profiling Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Tissue Testing (Solid Tissue Testing, Liquid Tissue Testing), By Cancer Panel Type (Single-Gene Panel, Multi-Gene Panel), By Cancer Type (Lung Cancer, Breast Cancer, Colon Cancer, Prostate Cancer, Others), By Application (Clinical, Research), By Technology (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescence In-Situ Hybridization (FISH), Immunohistochemistry (IHC), Others), By End-User (Hospitals, Clinical and Diagnostic Laboratories, Others), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 11.09 Billion
CAGR (2026-2031)	9.54%
Fastest Growing Segment	Liquid tissue testing
Largest Market	North America
Market Size (2031)	USD 19.16 Billion

Market Overview

The Global Genomic Cancer Panel & Profiling Market will grow from USD 11.09 Billion in 2025 to USD 19.16 Billion by 2031 at a 9.54% CAGR. Genomic cancer panels and profiling refer to diagnostic technologies that sequence specific genes or genomic regions to identify mutations and alterations driving tumor growth. The market is primarily driven by the increasing global prevalence of oncological diseases which necessitates personalized therapeutic approaches and the simultaneous reduction in costs associated with next-generation sequencing workflows. These factors collectively facilitate the integration of comprehensive molecular diagnostics into clinical practice to better guide targeted treatment decisions.

The expanding burden of disease underscores the necessity for these diagnostic tools. According to the American Cancer Society, in 2024, it is projected that new cancer cases in the United States will cross the 2 million mark for the first time. Despite this clear demand, the market faces a significant challenge regarding complex reimbursement landscapes. Inconsistent insurance coverage for broad molecular profiling remains a substantial barrier that may impede widespread adoption and restrict patient access to these essential testing capabilities.

Key Market Drivers

The rapid expansion of non-invasive liquid biopsy profiling is acting as a primary catalyst for market growth by overcoming the limitations of traditional tissue sampling. These blood-based tests allow for the detection of circulating tumor DNA, enabling real-time monitoring of disease progression and resistance mechanisms without the risks associated with surgical biopsies. This shift towards less invasive diagnostics is evidenced by the rising demand for clinical testing volumes. According to Guardant Health, November 2024, in the 'Third Quarter 2024 Financial Results', clinical test volume increased 21% year-over-year to reach 53,100 tests, highlighting the accelerated clinical uptake of these genomic profiling tools.

Simultaneously, the surge in biomarker-driven drug development is necessitating the integration of comprehensive genomic panels to identify eligible patients for targeted therapies. Pharmaceutical entities are increasingly allocating resources to precision oncology portfolios, which directly fuels the demand for companion diagnostics. According to Pfizer, October 2024, in the 'Third Quarter 2024 Results', the company reported that its oncology revenue was significantly bolstered by a $854 million global contribution from the acquired Seagen portfolio, demonstrating the commercial viability of biomarker-targeted treatments. This investment aligns with broader long-term projections of disease burden that require scalable diagnostic infrastructure. According to the World Health Organization, in 2024, the International Agency for Research on Cancer predicted that the global cancer burden will rise to more than 35 million new cases by 2050, underscoring the critical need for advanced profiling solutions.

Download Free Sample Report

Key Market Challenges

Complex reimbursement landscapes and inconsistent insurance coverage constitute a significant barrier hampering the growth of the Global Genomic Cancer Panel & Profiling Market. Clinical laboratories and hospital systems often hesitate to integrate comprehensive genomic profiling into standard care pathways when payment mechanisms remain opaque or unpredictable. This financial uncertainty compels healthcare providers to rely on narrower, less expensive diagnostic tests to avoid claim denials, thereby stifling the adoption of broader next-generation sequencing panels. As a result, the market struggles to expand its user base because the economic risk associated with performing these advanced diagnostics often outweighs the perceived clinical utility for financial administrators at medical facilities.

The disparity in payer policies directly reduces the total volume of testing performed and limits revenue potential for diagnostic companies. Without uniform mandates, patients frequently face prohibitive out-of-pocket costs which leads to high rates of test abandonment. According to the American Cancer Society Cancer Action Network, in 2024, legislation ensuring coverage for comprehensive biomarker testing had been enacted in only 16 states, leaving the vast majority of the United States population subject to fragmented and restrictive insurance determinations. This regulatory patchworks sustains a market environment where access is determined by geography and plan type rather than clinical necessity, effectively putting a ceiling on market penetration and growth.

Key Market Trends

The Integration of Artificial Intelligence in Data Interpretation is fundamentally reshaping the market by resolving the bottleneck of analyzing massive genomic datasets. As sequencing outputs grow in complexity, AI algorithms are becoming essential for curating clinical insights and identifying rare variant patterns that manual analysis often misses. This technological synergy is rapidly translating into commercial adoption, as diagnostic firms leverage AI to enhance precision medicine offerings and improve operational efficiency. According to Tempus AI, January 2025, in the 'Preliminary Fourth Quarter and Full Year 2024 Results', the company reported a full-year revenue of approximately $693 million, representing a 30% year-over-year growth driven largely by the robust uptake of its AI-enabled precision medicine and genomic profiling solutions.

Simultaneously, the market is witnessing a decisive Transition to Comprehensive Genomic Profiling (CGP), moving away from limited hotspot panels toward broad-spectrum sequencing. This shift is predicated on emerging clinical evidence that larger panels detect significantly more actionable alterations, thereby improving patient access to matched therapies compared to narrower diagnostic approaches. This superior clinical utility is encouraging healthcare systems to standardize broader testing protocols to minimize missed treatment opportunities. According to Illumina, November 2024, in the press release 'Comprehensive Genomic Profiling leads to better patient outcomes, new joint study says', a real-world study demonstrated that 67% of tumors from CGP-tested patients harbored actionable mutations, compared to only 33% of patients tested with smaller 50-gene panels.

Segmental Insights

Liquid tissue testing represents the fastest growing segment within the Global Genomic Cancer Panel and Profiling Market due to its distinct advantages over traditional solid tumor assessments. Unlike invasive surgical biopsies, this method analyzes circulating tumor DNA through standard blood draws, enabling safer and frequent monitoring of treatment response. This expansion is supported by regulatory bodies like the US FDA, which have granted approvals for multiple liquid biopsy companion diagnostics. These regulatory milestones validate the clinical utility of liquid testing, making it a preferred option when tissue availability is limited.

Regional Insights

North America maintains the leading position in the Global Genomic Cancer Panel & Profiling Market due to the widespread adoption of precision oncology and established healthcare infrastructure. The region benefits from a high concentration of key biotechnology companies and continuous investment in genomic research. Regulatory support from the U.S. Food and Drug Administration (FDA) facilitates the approval of companion diagnostics, driving clinical adoption. Furthermore, the Centers for Medicare & Medicaid Services (CMS) supports market expansion by providing reimbursement for genomic testing. These structural advantages and supportive policies collectively ensure the region remains the dominant market globally.

Recent Developments

• In November 2024, Tempus AI, Inc. announced a strategic collaboration with Flatiron Health to integrate its comprehensive genomic testing capabilities directly into the OncoEMR electronic medical record platform. This development is highly relevant to the Global Genomic Cancer Panel & Profiling Market as it embeds molecular profiling workflows into the daily practice of community oncologists. The integration allows providers to order tests and view results within their existing clinical systems, reducing administrative friction and accelerating the application of precision medicine. By enhancing the accessibility of genomic data at the point of care, this partnership aims to improve patient outcomes through more efficient data-driven treatment planning.
• In August 2024, Illumina, Inc. obtained FDA approval for its TruSight Oncology Comprehensive test, a distributable in vitro diagnostic kit that profiles over 500 genes. This approval, which included companion diagnostic indications, represents a significant advancement in the Global Genomic Cancer Panel & Profiling Market by enabling laboratories to perform comprehensive genomic profiling in-house. The test is designed to identify patients with solid tumors who harbor specific genomic alterations, such as NTRK gene fusions, facilitating matches to targeted therapies. This launch expands access to precision oncology by streamlining the identification of actionable biomarkers and clinical trial eligibility in a single assay.
• In July 2024, Guardant Health achieved a major regulatory milestone with the FDA approval of its Shield blood test for colorectal cancer screening. This product launch addresses a critical need in the Global Genomic Cancer Panel & Profiling Market by offering a non-invasive genomic profiling option for average-risk adults aged 45 and older. The test detects cancer-specific signals in the bloodstream, providing a convenient alternative to traditional methods and potentially increasing screening adherence. This development highlights the growing role of liquid biopsy technologies in early cancer detection, allowing providers to utilize genomic data to identify disease at improved rates compared to standard modalities.
• In March 2024, Bayer AG and Thermo Fisher Scientific Inc. entered into a collaboration to develop next-generation sequencing-based companion diagnostic assays, significantly impacting the Global Genomic Cancer Panel & Profiling Market. This partnership focuses on utilizing the Oncomine Dx Express Test on the Ion Torrent Genexus Dx System to identify patients eligible for Bayer’s precision cancer therapies. By enabling decentralized genomic testing with rapid turnaround times, the companies aim to provide clinicians with prompt, actionable insights. This initiative underscores the industry's drive to integrate comprehensive profiling into routine clinical practice, ensuring that patients receive appropriate targeted treatments faster than previously possible.

Key Market Players

• Agilent Technologies, Inc.
• ARUP Laboratories Inc
• Burning Rock Biotech Limited
• U.S. Caris MPI, Inc.
• Danaher Corporation
• Exact Sciences Corporation
• F. Hoffmann-La Roche Ltd
• Fulgent Genetics Inc.
• Illumina, Inc.
• Thermo Fisher Scientific Inc.

By Tissue Testing	By Cancer Panel Type	By Cancer Type	By Application	By Technology	By End-User	By Region
Solid Tissue Testing Liquid Tissue Testing	Single-Gene Panel Multi-Gene Panel	Lung Cancer Breast Cancer Colon Cancer Prostate Cancer Others	Clinical Research	Next-Generation Sequencing (NGS) Polymerase Chain Reaction (PCR) Fluorescence In-Situ Hybridization (FISH) Immunohistochemistry (IHC) Others	Hospitals Clinical and Diagnostic Laboratories Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Genomic Cancer Panel & Profiling Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Genomic Cancer Panel & Profiling Market, By Tissue Testing:

• Solid Tissue Testing
• Liquid Tissue Testing

• Genomic Cancer Panel & Profiling Market, By Cancer Panel Type:

• Single-Gene Panel
• Multi-Gene Panel

• Genomic Cancer Panel & Profiling Market, By Cancer Type:

• Lung Cancer
• Breast Cancer
• Colon Cancer
• Prostate Cancer
• Others

• Genomic Cancer Panel & Profiling Market, By Application:

• Clinical
• Research

• Genomic Cancer Panel & Profiling Market, By Technology:

• Next-Generation Sequencing (NGS)
• Polymerase Chain Reaction (PCR)
• Fluorescence In-Situ Hybridization (FISH)
• Immunohistochemistry (IHC)
• Others

• Genomic Cancer Panel & Profiling Market, By End-User:

• Hospitals
• Clinical and Diagnostic Laboratories
• Others

• Genomic Cancer Panel & Profiling Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE